BioMarin Q3 2026 Revenue Jumps 32% to $1.025 Billion
BioMarin posted strong third-quarter results driven by surging metabolic and skeletal drug sales, while updating full-year guidance amid order timing concerns.
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase compared with the same period a year earlier, according to the company's latest financial results release.
The revenue surge was led by a 44% year-over-year jump in sales tied to metabolic conditions treatments, while the company's skeletal conditions portfolio contributed an additional 12% year-over-year gain, underscoring broad-based commercial momentum across BioMarin's rare-disease drug lineup.
Read more Sporttrade Wins CFTC Approval as Derivatives Exchange and Clearinghouse →
Despite the headline beat, management revised its full-year 2026 guidance downward to account for uncertainty around order timing and the financial impact of two in-process research and development assets acquired during the period. Such acquired in-process R&D charges are standard accounting treatment when a company purchases pipeline assets that have not yet reached commercialization, and they can meaningfully weigh on reported earnings even when underlying operations remain strong.
The guidance update signals that while BioMarin's marketed products are generating accelerating demand, near-term financial forecasts remain sensitive to deal-related accounting and fluctuations in how distributor and hospital orders fall across quarters. Analysts and investors will likely focus on whether the metabolic conditions growth trajectory is sustainable heading into 2027 and how quickly the newly acquired pipeline assets could move toward regulatory submission.
Continue reading at All Financial Services & Investing.
